Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Conor predicts early 2007 US filing for CoStar drug-eluting stent:

This article was originally published in Clinica

Executive Summary

Conor Medsystems believes it could be set to submit a US marketing application for its CoStar drug-eluting stent early next year, pending favourable results from a pivotal trial of the device, which was recently reported to have enrolled all of its 1,700 assigned patients. The COSTAR II trial is comparing Conor's cobalt chromium paclitaxel-eluting stent with Boston Scientific's paclitaxel-eluting Taxus Express2 stent in de novo lesions in patients with single or multi-vessel coronary artery disease. The Menlo Park, California firm believes that an early 2007 PMA submission for CoStar could put it in line for receiving FDA approval in late 2007 or early 2008. CoStar was CE-marked earlier this year and is currently being marketed in certain countries in Europe, Latin America and Asia.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT051554

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel